1
|
Quintana ME, Cardoso NP, Pereyra R, Barone LJ, Barrionuevo FM, Mansilla FC, Turco CS, Capozzo AV. Interferon lambda protects cattle against bovine viral diarrhea virus infection. Vet Immunol Immunopathol 2020; 230:110145. [PMID: 33160262 DOI: 10.1016/j.vetimm.2020.110145] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 10/25/2020] [Accepted: 10/29/2020] [Indexed: 01/15/2023]
Abstract
Interferon lambda (IFN-λ) plays an important role in inducing an antiviral state in mucosal surfaces and has been used as an effective biotherapeutic against several viral diseases. Here we performed a proof of concept study on the activity of a biologically active recombinant bovine IFN-λ (rIFN-λ) produced in eukaryotic cells against Bovine Viral Diarrhea Virus (BVDV) in cattle. We first confirmed the lack of toxicity of different concentrations of rIFN-λ in bovine peripheral blood cells and the safety of its subcutaneous application in calves in doses up to 12 IU/kg. The antiviral activity of the rIFN-λ against BVDV was assessed in calves that were inoculated with 6 IU/kg of rIFN-λ (n = 4) or mock-treated (n = 2) two days before and after challenge with a BVDV type-2 non-cytopathic strain. Mock-treated animals developed respiratory disease, shedded the virus from 4 to 7 days post-infection (dpi) and had viremia between 4 and 14 dpi. Conversely, calves treated with rIFN-λ did not develop clinical symptoms. The virus was not found in nasal secretions or sera. Only one animal had a positive viral RNA detection in serum at 7 dpi. All infected animals treated with rIFN-λ increased systemic type-I IFNs levels at 4 dpi. The antiviral treatment induced an earlier onset of the anti-BVDV neutralizing antibodies. Altogether, these results constitute the proof-of-principle of bovine IFN-λ as an antiviral biotherapeutic to protect cattle against the clinical disease caused by BVDV.
Collapse
Affiliation(s)
- María Eugenia Quintana
- Instituto de Virología e Innovaciones Tecnológicas. IVIT, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) - Instituto Nacional de Tecnología Agropecuaria (INTA). Nicolás Repetto y Los Reseros s/n. Hurlingham, Buenos Aires, Argentina
| | - Nancy Patricia Cardoso
- Instituto de Virología e Innovaciones Tecnológicas. IVIT, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) - Instituto Nacional de Tecnología Agropecuaria (INTA). Nicolás Repetto y Los Reseros s/n. Hurlingham, Buenos Aires, Argentina
| | - Rodrigo Pereyra
- Área de Investigación en Sanidad Animal IIACS-CIAP- Estación Experimental Agropecuaria EEA, INTA Cerrillos, Salta, Argentina
| | - Lucas José Barone
- Instituto de Virología e Innovaciones Tecnológicas. IVIT, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) - Instituto Nacional de Tecnología Agropecuaria (INTA). Nicolás Repetto y Los Reseros s/n. Hurlingham, Buenos Aires, Argentina
| | - Florencia Mariel Barrionuevo
- Instituto de Virología e Innovaciones Tecnológicas. IVIT, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) - Instituto Nacional de Tecnología Agropecuaria (INTA). Nicolás Repetto y Los Reseros s/n. Hurlingham, Buenos Aires, Argentina
| | - Florencia Celeste Mansilla
- Instituto de Virología e Innovaciones Tecnológicas. IVIT, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) - Instituto Nacional de Tecnología Agropecuaria (INTA). Nicolás Repetto y Los Reseros s/n. Hurlingham, Buenos Aires, Argentina
| | - Cecilia Soledad Turco
- Instituto de Virología e Innovaciones Tecnológicas. IVIT, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) - Instituto Nacional de Tecnología Agropecuaria (INTA). Nicolás Repetto y Los Reseros s/n. Hurlingham, Buenos Aires, Argentina
| | - Alejandra Victoria Capozzo
- Instituto de Virología e Innovaciones Tecnológicas. IVIT, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) - Instituto Nacional de Tecnología Agropecuaria (INTA). Nicolás Repetto y Los Reseros s/n. Hurlingham, Buenos Aires, Argentina.
| |
Collapse
|
2
|
Production of biologically active feline interferon beta in insect larvae using a recombinant baculovirus. 3 Biotech 2018; 8:341. [PMID: 30073126 DOI: 10.1007/s13205-018-1369-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2018] [Accepted: 07/21/2018] [Indexed: 10/28/2022] Open
Abstract
Feline interferon beta is a cytokine that belongs to the type I IFN family, with antitumor, antiviral and immunomodulatory functions. In this work, recombinant feline interferon beta (rFeIFNβ) was expressed in insect larvae that constitute important agronomic plagues. rFeIFNβ accumulated in the hemolymph of Spodoptera frugiperda larvae infected with recombinant baculovirus and was purified by Blue-Sepharose chromatography directly from larval homogenates on day 4 post-infection. rFeIFNβ was recovered after purification with a specific activity of 1 × 106 IU mg-1. By this method, we obtained 8.9 × 104 IU of purified rFeIFNβ per larva. The product was biologically active in vitro, with an antiviral activity of 9.5 × 104 IU mL-1, as well as a potent antitumor activity comparable to that of the commercial FeIFNω. The glycosylation of rFeIFNβ was confirmed by peptide-N-glycosidase F digestion. Our findings provide a cost-effective platform for large-scale rFeIFNβ production in laboratory research or veterinary medicine applications.
Collapse
|
3
|
Smith ME, Targovnik AM, Cerezo J, Morales MA, Miranda MV, Talou JR. Integrated process for the purification and immobilization of the envelope protein domain III of dengue virus type 2 expressed in Rachiplusia nu larvae and its potential application in a diagnostic assay. Protein Expr Purif 2016; 131:76-84. [PMID: 27888023 DOI: 10.1016/j.pep.2016.11.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2016] [Revised: 11/18/2016] [Accepted: 11/19/2016] [Indexed: 12/24/2022]
Abstract
Dengue incidence has grown dramatically in the last years, with about 40% of the world population at risk of infection. Recently, a vaccine developed by Sanofi Pasteur has been registered, but only in a few countries. Moreover, specific antiviral drugs are not available. Thus, an efficient and accurate diagnosis is important for disease management. To develop a low-cost immunoassay for dengue diagnosis, in the present study we expressed the envelope protein domain III of dengue virus type 2 in Rachiplusia nu larvae by infection with a recombinant baculovirus. The antigen was expressed as a fusion to hydrophobin I (DomIIIHFBI) to easily purify it by an aqueous two-phase system (ATPS) and to efficiently immobilize it in immunoassay plates. A high level of recombinant DomIIIHFBI was obtained in R. nu, where yields reached 4.5 mg per g of larva. Also, we were able to purify DomIIIHFBI by an ATPS with 2% of Triton X-114, reaching a yield of 73% and purity higher than 80% in a single purification step. The recombinant DomIIIHFBI was efficiently immobilized in hydrophobic surface plates. The immunoassay we developed with the immobilized antigen was able to detect IgG specific for dengue virus type 2 in serum samples and not for other serotypes.
Collapse
Affiliation(s)
- María Emilia Smith
- Instituto NANOBIOTEC - Cátedra de Biotecnología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas, Junín 956, 1113, Ciudad Autónoma de Buenos Aires, Argentina.
| | - Alexandra Marisa Targovnik
- Instituto NANOBIOTEC - Cátedra de Biotecnología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas, Junín 956, 1113, Ciudad Autónoma de Buenos Aires, Argentina.
| | - Julieta Cerezo
- Instituto NANOBIOTEC - Cátedra de Biotecnología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas, Junín 956, 1113, Ciudad Autónoma de Buenos Aires, Argentina.
| | - María Alejandra Morales
- Laboratorio de Arbovirus, Instituto Nacional de Enfermedades Virales Humanas (INEVH) "Dr. Julio I. Maiztegui"- ANLIS, Monteagudo 2510, 2700, Pergamino, Buenos Aires, Argentina.
| | - María Victoria Miranda
- Instituto NANOBIOTEC - Cátedra de Biotecnología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas, Junín 956, 1113, Ciudad Autónoma de Buenos Aires, Argentina.
| | - Julián Rodríguez Talou
- Instituto NANOBIOTEC - Cátedra de Biotecnología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas, Junín 956, 1113, Ciudad Autónoma de Buenos Aires, Argentina.
| |
Collapse
|
4
|
Villaverde MS, Targovnik AM, Miranda MV, Finocchiaro LME, Glikin GC. Cytotoxic effects induced by interferon-ω gene lipofection through ROS generation and mitochondrial membrane potential disruption in feline mammary carcinoma cells. Cytokine 2016; 84:47-55. [DOI: 10.1016/j.cyto.2016.05.018] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Revised: 05/03/2016] [Accepted: 05/18/2016] [Indexed: 02/05/2023]
|